Healthcare >> Sector Roundtables >> May 29, 2000
ROBERT TOTH, JR. is a Senior Analyst with the Prudential Vector
Healthcare Group, covering biotechnology companies focusing on cancer
therapeutics, genomic platforms, and neuroscience applications. He
joined Prudential Securities via the July 1999 acquisition of Vector
Securities International, Inc. Prior to joining Vector, Mr. Toth served
as Business Development Analyst with the biotechnology company
Connectics Corp. He received his BBA in Biology and Biochemistry from
California State Polytechnic University, and an MBA from the University
of Washington School of Business. Profile
PETER F. DRAKE, PhD is a Managing Director of Equity Research with
Prudential Vector Healthcare Group, where he also serves as co-Founder
and Executive Vice President of Vector Securities International.
Previously, he served as a Senior Research Analyst covering
biotechnology and biomedical products with Kidder, Peabody. Dr. Drake
holds a Doctoral degree in Neurobiology and Biochemistry from Bryn Mawr
College and a CBA from the Wharton School of Business at the University
of Pennsylvania. Profile
JOHN S. SONNIER is a Senior Biotechnology Analyst with the Prudential
Vector Healthcare Group, focusing on small, mid- and large-cap companies
in the areas of infectious disease, transfusion medicine and
neuroscience. He joined Prudential Securities via the July 1999
acquisition of Vector Securities International, Inc. Prior to joining
Vector, Mr. Sonnier spent eight years in the pharmaceutical industry at
Johnson & Johnson and Baxter and, most recently, as the Senior
Healthcare Planning Manager at Baxter Healthcare Corporation, Biotech
Group. He received his BS degree in Business from the University of
Southern Mississippi. Profile
Prudential Vector Healthcare Group takes to the biotechnology sector?
Mr. Drake: I'd be glad to. First of all, we take a
